The deal will see Kumquat utilise its small molecule immune-oncology platform to discover novel clinical assets
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.